ES8706965A1 - Un metodo de formacion de un conjugado de proteina y quelato metalico - Google Patents

Un metodo de formacion de un conjugado de proteina y quelato metalico

Info

Publication number
ES8706965A1
ES8706965A1 ES554387A ES554387A ES8706965A1 ES 8706965 A1 ES8706965 A1 ES 8706965A1 ES 554387 A ES554387 A ES 554387A ES 554387 A ES554387 A ES 554387A ES 8706965 A1 ES8706965 A1 ES 8706965A1
Authority
ES
Spain
Prior art keywords
forming
metal chelate
protein conjugate
chelate protein
metal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES554387A
Other languages
English (en)
Other versions
ES554387A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of ES8706965A1 publication Critical patent/ES8706965A1/es
Publication of ES554387A0 publication Critical patent/ES554387A0/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

METODO PARA FORMAR UN CONJUGADO DE PROTEINA Y QUELATO METALICO. COMPRENDE: A) PONER EN CONTACTO UN METAL, EN AUSENCIA DE PROTEINA CON UN QUELATO BIFUNCIONAL; Y B) MEZCLAR AL QUELATO METALICO CON UNA PROTEINA, EN UNA SOLUCION ACUOSA A UN PH ENTRE 6 Y 11, PARA FORMAR UN CONJUGADO ESTABLE DE PROTEINA Y QUELATO METALICO. EL METAL ES RADIONUCLIDO O FLUORESCENTE Y SE ELIGE ENTRE GADOLINIO O TRIENO; LA PROTEINA SE ELIGE ENTRE UNA PROTEINA DE LA SANGRE Y UN ANTICUERPO MONOCLONAL; Y EL QUELATO BIFUNCIONAL CONTIENE UN GRUPO FUNCIONAL UNIDO A UN ATOMO DE CARBONO DEL ESQUELETO DE QUELATO Y ES ESTABLE EN SOLUCION ACUOSA DILUIDA Y ES UN GRUPO ESTER DE N-HIDROXISUCCINIMIDA. SE UTILIZA PARA FORMAR UTILES EN LA TERAPIA Y DIAGNOSTICO DE LOS TUMORES.
ES554387A 1985-04-26 1986-04-25 Un metodo de formacion de un conjugado de proteina y quelato metalico Expired ES8706965A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/727,919 US4824986A (en) 1985-04-26 1985-04-26 Metal chelate protein conjugate

Publications (2)

Publication Number Publication Date
ES8706965A1 true ES8706965A1 (es) 1987-07-01
ES554387A0 ES554387A0 (es) 1987-07-01

Family

ID=24924643

Family Applications (1)

Application Number Title Priority Date Filing Date
ES554387A Expired ES8706965A1 (es) 1985-04-26 1986-04-25 Un metodo de formacion de un conjugado de proteina y quelato metalico

Country Status (10)

Country Link
US (1) US4824986A (es)
EP (3) EP0220279A1 (es)
JP (1) JPS62502618A (es)
KR (1) KR870700639A (es)
CN (1) CN86103488A (es)
AU (2) AU596590B2 (es)
BR (1) BR8606644A (es)
DK (1) DK627286A (es)
ES (1) ES8706965A1 (es)
WO (1) WO1986006384A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227474A (en) * 1987-02-13 1993-07-13 Abbott Laboratories Bifunctional chelating agents
DE3710730A1 (de) * 1987-03-31 1988-10-20 Schering Ag Substituierte komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel
DE3728525A1 (de) * 1987-08-24 1989-03-16 Schering Ag Mehrkernige substituierte komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel
US5612016A (en) * 1988-04-01 1997-03-18 Immunomedics, Inc. Conjugates of antibodies and bifunctional ligands
US5059541A (en) * 1988-04-29 1991-10-22 Neorx Corporation Minimal derivatization of proteins
NZ231180A (en) 1988-10-31 1994-11-25 Dow Chemical Co Bifunctional chelants;complexes,conjugates and pharmaceutical compositions thereof
BR8907282A (pt) * 1988-12-23 1991-03-12 Dow Chemical Co Processo para preparar complexos de metal funcionalizados com isotiocianato
US5364613A (en) * 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US6039931A (en) * 1989-06-30 2000-03-21 Schering Aktiengesellschaft Derivatized DTPA complexes, pharmaceutical agents containing these compounds, their use, and processes for their production
DE3922005A1 (de) * 1989-06-30 1991-01-10 Schering Ag Derivatisierte dtpa-komplexe, diese verbindungen enthaltende pharmazeutische mittel, ihre verwendung und verfahren zu deren herstellung
US5695739A (en) * 1989-06-30 1997-12-09 Schering Aktiengesellschaft Derivatized DTPA complexes, pharmaceutical agents containing these compounds, their use, and processes for their production
US5112946A (en) * 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5686410A (en) * 1989-07-20 1997-11-11 Novartis Ag Polypeptide derivatives
US5124471A (en) * 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand
DE4136489A1 (de) * 1991-11-06 1993-05-13 Bayer Ag Neue diethylentriamin-derivate und deren verwendung zu diagnostischen und therapeutischen zwecken
US5494935A (en) * 1992-01-17 1996-02-27 University Of Utah Research Foundation Methods for oral decorporation of metals
US5403862A (en) * 1992-01-17 1995-04-04 University Of Utah Research Foundation Method for oral decorporation of metals
US5292729A (en) * 1992-08-14 1994-03-08 Albion International, Inc. II-bond aromatic vitamin chelates
US5672335A (en) * 1994-11-30 1997-09-30 Schering Aktiengesellschaft Use of metal complexes as liver and gallbladder X-ray diagnostic agents
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
IT1291623B1 (it) * 1997-04-18 1999-01-11 Bracco Spa Procedimento per la coniugazione di chelanti con molecole contenenti gruppi amminici
US6740756B1 (en) * 1998-07-07 2004-05-25 Smithkline Beecham Corporation Fluorescent lanthanide chelates
MY133346A (en) * 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
US7045605B2 (en) 2001-06-01 2006-05-16 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
WO2003024388A2 (en) 2001-09-20 2003-03-27 Cornell Research Foundation, Inc. Methods and compositions for treating and preventing skin disorders using binding agents specific for psma
DE60323677D1 (de) 2003-01-10 2008-10-30 Millennium Pharm Inc Verfahren zur bestimmung des wiederauftretens von prostata krebs
EP1689448B1 (en) 2003-12-01 2015-07-29 Immunomedics Inc. Method for preparing dota-antibody conjugates
JP2022509239A (ja) * 2018-11-28 2022-01-20 キューブ バイオテック ゲーエムベーハー 固相キレート材、その製造方法およびタンパク質の精製におけるその使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1178951A (en) * 1980-03-18 1984-12-04 Claude F. Meares Chelating agents and method
US4622420A (en) * 1980-03-18 1986-11-11 The Regents Of The University Of California Chelating agents and method
DE3239410A1 (de) * 1981-10-27 1983-05-19 Hybritech Inc., 92121 San Diego, Calif. Monoklonale antikoerper zu tumorassoziiertem antigen, zusammensetzungen, welche diese enthalten und deren anwendung zum tumornachweis
CA1225930A (en) * 1982-06-07 1987-08-25 Otto A. Gansow Metal chelate conjugated monoclonal antibodies
US4454106A (en) * 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
US4472509A (en) * 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4652519A (en) * 1983-02-03 1987-03-24 Yeda Research And Development Company Limited Bifunctional chelating agents and process for their production

Also Published As

Publication number Publication date
EP0220279A1 (en) 1987-05-06
CN86103488A (zh) 1987-05-27
EP0315220A1 (en) 1989-05-10
AU4932490A (en) 1990-06-07
US4824986A (en) 1989-04-25
JPS62502618A (ja) 1987-10-08
EP0355860A1 (en) 1990-02-28
BR8606644A (pt) 1987-08-04
KR870700639A (ko) 1987-12-30
AU596590B2 (en) 1990-05-10
AU5780086A (en) 1986-11-18
DK627286A (da) 1987-02-26
DK627286D0 (da) 1986-12-23
WO1986006384A1 (en) 1986-11-06
ES554387A0 (es) 1987-07-01

Similar Documents

Publication Publication Date Title
ES8706965A1 (es) Un metodo de formacion de un conjugado de proteina y quelato metalico
GB2171303B (en) Erythropoietin for the treatment of anemia caused by malignant tumors
GR900100504A (en) Novel antibodies reacting to the human cancerous tumours
RU93051543A (ru) Производные акридина, способ получения, фармацевтическая композиция и способ лечения злокачественных опухолей
GB8616511D0 (en) Diagnosis of malignant tumours
GB2093845B (en) Platinum-diamine complexes useful for the treatment of cancer
HU895608D0 (en) Process for the preparation of chelates containing ortho ligating functional group and complexes thereof
GB8615916D0 (en) Bone-seeking complexes of technetium-99m
GR1003189B (el) Μεθοδοι προληψεως του καρκινου του μαστου
NZ237688A (en) Antibody-cytotoxic immunoconjugate-containing compositions and cancer treatment
ZA837857B (en) Platinum-diamine complexes,a process for the preparation thereof and a process for the preparation of a medical composition using such a complex for the treatment of cancer
AU584918B2 (en) Aminocarboxylic acid complexes for the treatment of calcific tumors
ES8404693A1 (es) Procedimiento de preparacion de nuevos amino-14 esteroides.
ES2019713A6 (es) Un procedimiento para preparar derivados clorados de adenosina.
HUT45622A (en) Process for making medical compositions for diagnosing tumours
EP0339097A4 (en) Method for diagnosis of liver cancer
ZA856921B (en) Aminocarboxylic acid complexes for the treatment of calcific tumors
GB8702062D0 (en) Metal complexes for diagnosis & therapy
ES8507140A1 (es) Procedimiento para la preparacion del citrato de la (-) vinburnina
IE782453L (en) In vitro method for diagnosis of malignant tumours
IE850003L (en) Breast cancer diagnosis
TWI265811B (en) Extended type 1 chain glycosphingolipids as tumor-associated antigens
YU44277B (en) Process for producing iron helate for farm use as manure